To add to this complexity, dosing of STING agonists is not trivial as, paradoxically, lower doses of the CDN mimic ADU-S100 injected into tumours produced higher levels of tumour-specific circulating CD8+ T-cells compared with higher doses [93]. The gene discussed is CD8A; the disease is neoplasm.